# Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

Study · id `cardio:ct-nct05874635` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05874635](<https://clinicaltrials.gov/study/NCT05874635>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05874635

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 20000 participants.

## Technical summary

Registry record NCT05874635. Allocation not applicable; no masking; primary purpose treatment. Start 2023-05-11 (actual); primary completion 2028-05-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 20000 participants (planned count; ClinicalTrials.gov record NCT05874635, source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)
- Started: 2023-05-11 (actual) (ClinicalTrials.gov record NCT05874635, source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)
- Primary completion: 2028-05-10 (anticipated) (ClinicalTrials.gov record NCT05874635, source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)
- Completion: 2029-05-10 (anticipated) (ClinicalTrials.gov record NCT05874635, source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05874635, source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05874635-2025-08-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
- Condition: Weight Loss
- Condition: Metabolic Syndrome
- Condition: Diabetes Mellitus, Type 2
- Condition: Central Obesity
- Condition: Insulin Resistance
- Condition: Glucose Intolerance
- Condition: Metabolic Glucose Disorders
- Intervention (Device): Continuous Glucose Monitor Device
- Lead sponsor: Signos Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: a47909d70f746e6fd37a819a1cef6835a705c17fba5947d7089f98cf0dbe4d06
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
